All

API

FDF

Price

Services

Excipients

Enquiries

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace

Market Place

Post Enquiry

Grow Your Pharma Business Digitally

Scorr-Insert

X

Find Novel Oncology Drugs in Preclinical Development in GERMANY

A collaboration with SCORR Marketing

All Data

Filters

refresh

×

FILTER DATA :

News Type

Company

Product Type

Deal Size

Upfront Payment

refresh

Product Type

Companies

Immatics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

GERMANY Germany

Post An Enquiry

ASCO 2020

Participation Not Confirmed

Update your events

GSK pays $50M for 2 solid tumor cell therapies from Immatics

Contact the Supplier

Lead Product(s): Allogeneic T-cell therapies

Therapeutic Area: Oncology

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: GlaxoSmithKline plc

Deal Size: $600.0 million Upfront Cash: $50.0 million

Deal Type: Collaboration February 20, 2020

Details:

GSK to obtain access to two Immatics TCR-T programs, further advancing their commitment to the field of cell therapies.

BioNTech SE

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

GERMANY Germany

Post An Enquiry

ASCO 2020

Participation Not Confirmed

Update your events

BioNTech Announces Publication of Preclinical Data for First-in-Kind CAR-T Cell Therapy Approach Targeting Solid Tumors in Science

Contact the Supplier

Lead Product(s): BNT211

Therapeutic Area: Oncology

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 02, 2020

Details:

The data for BNT211 reports Claudin 6 as a novel target for CAR-T cell therapy of solid tumors and introduces CARVac, a new RNA vaccine promoting the amplification of CAR-T cells in vivo.